November 28, 2006

Dear Board Members:

Annual Report to the Board

This report is presented to the Board of Directors at the 2006 annual meeting of CLL Topics, Inc. It has been an eventful year with a number of important achievements in supporting clinical research in CLL and in our patient education and advocacy mission.

1. We reviewed and approved a grant application from Professor Ronald P. Taylor at the University of Virginia, Charlottesville, VA for a study to evaluate low dose subcutaneous Rituxan as a therapeutic agent in CLL. We disbursed an amount of $25,000 to the University in September, 2006. This amount completes our indicated level of support for this project.

2. We reviewed and approved a grant of $20,000 to the Fred Hutchinson Cancer Research Center at the University of Washington, Seattle, WA for a study to evaluate the combination of fenretinide and Rituxan as a therapeutic protocol for CLL. The principal investigator for this trial is Professor Ajay Gopal. Our support of this trial, which is substantially funded by the NCI, was instrumental in having CLL patients included in the study. This trial is in its initial dose escalation phase; our funding will be disbursed when this phase is over and the trial enters the combination therapy phase. Our commitment to fund is conditional only on the IRB approval for the combination therapy phase of the clinical trial.

3. We proposed and initiated a clinical trial to be conducted under the guidance of Professor Terry Hamblin at the Royal Bournemouth Hospital in the UK. This trial will test the efficacy of imiquimod as an immune modulator to increase the response rate of CLL patients to influenza vaccination. The protocol for this trial is currently going through review at the relevant ethics committee and regulatory authorities. CLL Topics reviewed and approved a grant of $20,000 to the Royal Bournemouth Hospital for this trial. The disbursement of this grant is conditional on the receipt of regulatory approval for the trial to proceed.

4. Since the date of our incorporation as a non-profit our fund-raising now stands at $171,030.27 from 472 donors, principally CLL patients and their families and friends.

5. Donations received this year through November 28, 2006 have totaled $71,027.69. The arrangement for donation receipts through PayPal is functioning well. Receipts through this method have totaled $14,772.46 so far in 2006.

6. Topics Alerts has increased its subscriber enrollment to 1,656. Sixty four Alerts have been issued so far this year.


Dedicated to the Fight Against Chronic Lymphocytic Leukemia
7. Traffic to the CLL Topics online publication has grown steadily and now stands at over 30,000 visits a month. Since January 2006, we have published twenty six new major articles on the website. We have maintained exactly 100% uptime since upgrading our hosting to a business-grade server in January 2005.

8. The website generates a constant stream of feedback, almost entirely positive, and many requests for information and assistance. The officers of the Corporation currently respond to over 1,000 email communications a month from patients and professionals in the field.

9. We have completed three years of regulatory reporting to the State of Arizona and the IRS and continue to be registered with Guidestar, the national database of non-profit organizations. During 2006 we have received accreditation from HONcode, the international non-profit agency that rates the credibility and transparency of health information on the net. As a member of this online registry we are pledged to follow the HONcode ethical principles for publishing health information on the Web.

10. CLL Topics received media credentials to send reporters to the 2006 Annual Meeting of the American Society of Hematology in Orlando, Florida, December 8-12. We were not able to send the team of reporters in 2005 for unanticipated medical reasons.

11. CLL Topics was the subject of positive press coverage in general interest articles that appeared in the Wall Street Journal (March 21, 2006) and the Washington Post (August 1, 2006).

12. We have also received calls from the financial press interested in our discussion of drugs used in the treatment of CLL and presumably the companies that manufacture or market them.

13. Chaya Venkat was invited to make a presentation at the UK CLL Forum, a meeting of professional scientists and clinicians, on May 10, 2006. The presentation, the only one representing the views of the patient community, was well received. This was also the occasion on which a discussion was initiated on the Corporation’s support of the clinical trial in point 1 above - and other possible projects.

We would like to thank the members of our Board of Directors that was elected to office for a one-year term on December 13, 2005, and two new board members who were elected on June 13, 2006. Your guidance, oversight and assistance have been extremely valuable. We are very pleased that eight of the nine members of the outgoing Board have agreed to our request to stay on as members of the new Board for 2007 and contribute their efforts, time and talent to our mission for another year.

Judith E. Fisher, who has served on the CLL Topics Board since the first full Board was elected on December 9, 2003, is unable to continue her participation on the Board for health reasons. We are grateful for her generous contribution of time, energy and talents to our cause and wish her the very best results from her ongoing therapy for lung cancer. A vote of thanks to Dr. Fisher is a formal part of management’s draft resolutions for consideration by the Board at this annual meeting.
It is with pleasure we announce the following slate of directors for re-election in our annual meeting of November 28, 2006:

David Arenson  
Robert J. Blake  
Peter F. Carpenter  
William W. Duffy, II  
Loyd Keith Friedlander  
Wendy Ramsey  
Chaya Venkat  
P. C. Venkat

Very truly yours,

____________________  
Chaya Venkat  
President  
& Treasurer  
CLL Topics, Inc.

____________________  
P. C. Venkat  
Vice President  
& Secretary  
CLL Topics, Inc.